Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

[1]  J. Ward.  The Nobel Prize for discovery of HCV is a call to end hepatitis , 2020, The Lancet.

[2]  M. Śpiewak,et al.  Management of hepatitis C in children and adolescents during COVID-19 pandemic , 2020, World journal of hepatology.

[3]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[4]  J. Pawlotsky,et al.  Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.

[5]  J. Lazarus,et al.  Global timing of hepatitis C virus elimination in high-income countries: an updated analysis , 2020, Journal of Hepatology.

[6]  J. J. Moreno,et al.  Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry , 2020, Journal of Hepatology.

[7]  N. Janjua,et al.  Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment , 2020, Journal of Hepatology.

[8]  F. Ponziani,et al.  Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver , 2020, Digestive and Liver Disease.

[9]  D. Dieterich,et al.  Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. , 2020, European journal of gastroenterology & hepatology.

[10]  I. Ntalla,et al.  Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[11]  B. Bacon,et al.  Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection , 2020, Advances in Therapy.

[12]  T. Berg,et al.  Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper , 2020, JHEP Reports.

[13]  M. Buti,et al.  Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. , 2020, Journal of hepatology.

[14]  A. Alberti,et al.  Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. , 2019, Journal of hepatology.

[15]  F. Mcphee.  Developments in the treatment of HCV genotype 3 infection , 2019, Expert review of anti-infective therapy.

[16]  M. Copetti,et al.  SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study , 2019, Cells.

[17]  T. Berg,et al.  Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry , 2019, Alimentary pharmacology & therapeutics.

[18]  S. Sarin,et al.  Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India , 2019, Hepatology International.

[19]  O. Weiland,et al.  Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden , 2018, Infectious diseases.

[20]  M. Buti,et al.  Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. , 2018, Gastroenterology.

[21]  C. Sarrazin,et al.  High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection , 2018, Alimentary pharmacology & therapeutics.

[22]  Brian L. Pearlman,et al.  Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. , 2017, Gastroenterology.

[23]  E. Daar,et al.  Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[25]  A. Thompson.  Australian recommendations for the management of hepatitis C virus infection: a consensus statement , 2016, The Medical journal of Australia.

[26]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[27]  American association for the study of liver diseases , 1992 .

[28]  T. Chalmers.  American Association for the Study of Liver Diseases , 1959 .

[29]  D. Brainard,et al.  Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis , 2018 .

[30]  S. Erlinger,et al.  European Association for the Study of the Liver , 2006 .